Nutex Health financials
$210.10−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $210.8M | $216.5M | $151.7M | $267.8M | $244.0M | $211.8M | $257.6M | $78.8M | $76.1M | $67.5M | $69.7M | $62.7M |
| Gross profit | $210.8M | $216.5M | $151.7M | $267.8M | $244.0M | $211.8M | $257.6M | $78.8M | $76.1M | $67.5M | -$4.4M | $62.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −6.3% | 100.0% |
| Operating income | $121.7M | $81.3M | $30.9M | $130.4M | $33.7M | $80.7M | $121.4M | $9.7M | $5.3M | $1.4M | -$26.1M | -$821.2K |
| Net income | $65.8M | $46.8M | $11.8M | $55.4M | -$17.7M | $21.2M | $61.6M | -$8.8M | -$364.0K | -$364.0K | -$31.6M | -$5.5M |
| Net margin | 31.2% | 21.6% | 7.8% | 20.7% | −7.3% | 10.0% | 23.9% | −11.2% | −0.5% | −0.5% | −45.4% | −8.8% |
| Diluted EPS | $9.38 | $6.52 | $1.60 | $7.76 | $-2.95 | $3.33 | $8.74 | $-1.72 | $-0.07 | $-0.08 | $-1.83 | $-1.25 |
| EBITDA | $127.0M | $86.8M | $36.1M | $135.4M | $38.9M | $85.8M | $119.6M | $15.1M | $16.5M | $5.6M | $4.1M | $4.0M |
| Operating cash flow | $34.2M | $75.5M | $70.4M | $99.5M | $27.3M | $51.0M | $54.0K | $6.8M | $13.3M | $3.1M | -$1.8M | $2.0M |
| Free cash flow | $31.7M | $74.3M | $69.0M | $99.2M | $26.5M | $50.9M | -$341.0K | $6.2M | $12.7M | $2.3M | -$2.6M | -$907.2K |
| Diluted shares | 7.0M | 7.2M | 7.4M | 7.2M | 6.0M | 6.5M | 7.0M | 5.1M | 5.0M | 4.8M | 17.3M | 4.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.2M | $207.3M | $185.6M | $166.0M | $96.7M | $84.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $315.9M | $317.3M | $319.2M | $326.1M | $312.4M | $308.9M |
| Total assets | $964.6M | $957.3M | $918.5M | $964.5M | $841.0M | $761.9M |
| Total liabilities | $457.3M | $515.3M | $495.1M | $526.5M | $504.2M | $506.6M |
| Shareholders' equity | $507.3M | $442.1M | $423.4M | $438.0M | $336.9M | $255.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology